AstraZeneca has agreed to acquire Alexion Pharmaceuticals for $39 billion; CDC issues coronavirus disease 2019 (COVID-19) vaccine guidance for those with a history of severe reactions to vaccines; 2.9 million COVID-19 vaccine doses began traveling this past weekend to all 50 states.
The Wall Street Journal reports that AstraZeneca has agreed to acquire Alexion Pharmaceuticals for $39 billion, a move that will seek to improve the British drugmaker’s influence in rare diseases. Notably, a majority of Alexion’s $6 billion in annual sales derives from its drug eculizumab (Soliris), which treats a rare blood disorder. Executives of AstraZeneca said the deal will help Alexion expand drug sales in new markets, particularly China, and will reduce infrastructure costs and improve profit margins for the company.
Yesterday, the CDC issued guidance stating that people who have experienced severe reactions to prior vaccines or injectable drugs can still take the Pfizer/BioNTech vaccine for coronavirus disease 2019 (COVID-19). Conversely, an earlier proposal issued on Saturday recommended against vaccination for those with severe allergic reactions. As reported by STAT, the CDC’s new guidance says that those who fall into this severe allergy group should discuss risks with their doctors and be monitored for 30 minutes after administration.
According to The New York Times, 2.9 million doses of the Pfizer/BioNTech COVID-19 vaccine began traveling this past weekend to all 50 states following the FDA’s emergency authorization, with the first injections expected to be administered today to high-risk health care workers. Along with each delivery of the vaccine, states will receive dry ice and special containers to keep the doses sufficiently cold for up to 10 days. Pfizer stated that it can provide up to 25 million doses of the vaccine to the United States by the end of this year.
NCCN Guidelines Update Adds Momelotinib Below Ruxolitinib for High-, Low-Risk Myelofibrosis
January 23rd 2024Momelotinib was given category 2A and 2B status for patients with high- and low-risk myelofibrosis (MF) and MF with anemia. However, ruxolitinib retains a higher category of recommendation as a treatment for patients with MF.
Read More
Oncology Onward: A Conversation With Dr Shereef Elnahal, Under Secretary for Health
April 20th 2023Shereef Elnahal, MD, MBA, under secretary for health at the Veterans Health Administration (VHA), sat for a conversation with our hosts Emeline Aviki, MD, MBA, Memorial Sloan Kettering Cancer Center, and Stephen Schleicher, MD, MBA, Tennessee Oncology, that covered the cancer footprint of the VHA.
Listen
Interventions Needed to Increase DMT Uptake in Sickle Cell Disease
December 26th 2023A recent study found that uptake of disease-modifying therapies (DMTs) has been low among patients with sickle cell disease, suggesting that more interventions that consider individual patient characteristics are needed to improve adoption.
Read More
Exploring Payer Coverage Decisions Following FDA Novel Drug Approvals
May 3rd 2022On this episode of Managed Care Cast, Ari D. Panzer, BS, lead author and researcher, then at Tufts Medical Center—now at Duke University—discusses the findings from his team’s investigation into coverage decisions by health plan insurers of the 66 drugs approved by the FDA in 2018.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More